Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

viiv healthcare uk ltd - fosamprenavir calcium - tablet - 700mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

viiv healthcare uk ltd - fosamprenavir calcium - oral suspension - 50mg/1ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

state of florida doh central pharmacy - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - lexiva® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with lexiva plus ritonavir in protease inhibitor-experienced patients: lexiva is contraindicated: drug class/drug name clinical comment alpha 1-adrenoreceptor antagonist: alfuzosin potentially increased alfuzosin concentrations can result in hypotension. antiarrhythmics: flecainide, propafenone potential for serious and/or life-threatening reactions such as cardiac arrhythmias secondary to increases in plasma concentrations of antiarrhythmics if lexiva is co-prescribed with ritonavir . antimycobacterials: rifampina may lead to loss of virologic response and possible resistance to lexiva or to the class of protease inhibitors. ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by pe

Izrael - angleščina - Ministry of Health

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

Izrael - angleščina - Ministry of Health

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

Japonska - angleščina - すりの適正使用協議会 RAD-AR Council, Japan

viiv healthcare k.k. - fosamprenavir calcium hydrate - pale reddish white tablet, major axis: 20.5 mm, minor axis: 9.5 mm, thickness: 7.4 mm

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fosamprenavir calcium -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fosamprenavir calcium -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fosamprenavir calcium -

Izrael - angleščina - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - efavirenz - film coated tablets - efavirenz 600 mg - efavirenz - efavirenz - stocrin in combination with other antiretroviral agents, is indicated for the treatment of hiv-1-infection .